OR WAIT null SECS
Nanoform Finland will be initiating the first human trial of a drug candidate nanoformed using the company’s CESS technology in 2020.
Nanoform Finland has revealed, in an Oct. 20, 2020 press release, that it will be initiating the first human trial of a drug candidate nanoformed using the company’s Controlled Expansion of Supercritical Solutions (CESS) technology during the fourth quarter of 2020.
The innovative nanoparticle medicine enabling company has reported that dosing will commence before the end of 2020 and results are expected to be available before the end of the second quarter on 2021. In the clinical trial, which is being performed in partnership with Quotient Sciences, Nanoform will investigate the behavior of an oral immediate release nanoformed formulation of piroxicam.
“The commencement of the first ever human trial of a drug nanoformed using our proprietary CESS technology is something we have been working tirelessly toward for many years, and we are very proud that our hard work has paid off in making the trial a reality ahead of schedule,” said Professor Edward Hæggström, Nanoform’s CEO, in the press release.
“Over the years, we have conducted hundreds of development programs on new drug candidates and we are incredibly pleased to be supporting Nanoform to validate their CESS technology,” added Mark Egerton, CEO of Quotient Sciences, in the press release. “We are committed to helping our customers bring new medicines to patients and eagerly await the outcome of the trial.”